The brain predicts what moving eyes will see

Article

A new study conducted by researchers at the University of Aberdeen, Scotland, has found that the brain predicts the consequences of eye movement even before the eyes take in a new scene.

A new study conducted by researchers at the University of Aberdeen, Scotland, has found that the brain predicts the consequences of eye movement even before the eyes take in a new scene.

The study published in the Journal of Vision asked subjects to move their eyes to a clock with a fast-moving hand and report the time immediately. The average reported time was 39 milliseconds before the actual time. As a control, the clock was moved instead of the eyes and the average reported time was 27 milliseconds after the actual time.

The results of study reveal a moment in time when things are not perceived as they actually are. It is thought that the prediction is a result of remapping, where neurons involved in visual perception become active or dormant in order to help the brain maintain stable vision.

“Remapping allows locations to be continuously represented across the eye movement by maintain both current and expected locations simultaneously, facilitating the transition between the two,” stated the report.

The authors, including lead researcher Amelia Hunt PhD, believe that further research is required to examine under what circumstances predictive processes occur, what function they serve and how much they influence our perception of events.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.